Supplemental Figure 5: Drug combinations in ABC-DLBCL.
Synergy experiments were performed with the indicated compounds using a 72h Alamar Blue assay and synergy scores were calculated as described in the Materials and Methods section.
Supplemental Figure 6: Proposed model for regulation of mTOR signaling in DLBCL.
These data support a model whereby mTOR activation is regulated by multiple inputs in DLBCL, including AKT, BCR/NF-κB signaling, and PIM. The balance of these inputs may be determined by the genetic background of the cell line or tumor, with ABC-type lines carrying activation mutations in CD79A/B requiring BTK signaling, wheras other ABC-type lines expressing high levels of PIM2 do not require this pathway. GCB-DLBCL appear to rely on the canonical signaling pathway through AKT to mTOR.
